Deepa Jagadeesh
A5013162117- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- T-cell and Retrovirus Studies
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Renal Transplantation Outcomes and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Cytomegalovirus and herpesvirus research
- Cancer Genomics and Diagnostics
- Cancer survivorship and care
Cleveland Clinic
2016-2025
Case Comprehensive Cancer Center
2015-2024
University Hospitals Seidman Cancer Center
2020-2022
Cancer Institute (WIA)
2020-2022
Levine Cancer Institute
2019
Case Western Reserve University
2018
University of Massachusetts Chan Medical School
2011-2014
UMass Memorial Health Care
2012
UMass Memorial Medical Center
2012
Dana-Farber Cancer Institute
2005
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic lymphoma, anaplastic large cell lymphoma kinase–positive, kinase–negative, and enteropathy-associated lymphoma. This discussion section focuses on diagnosis treatment PTCLs as outlined in NCCN Guidelines T-Cell Lymphomas.
<h3>Background</h3> Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. <h3>Patients and methods</h3> This phase II study (ELM-2; NCT03888105) evaluated odronextamab in patients with R/R follicular lymphoma after two or more lines systemic therapy. Patients received intravenous 21-day cycles, step-up dosing cycle 1 help...
We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time SOT-to-PTLD was 54 months, 79% had kidney SOT, histology monomorphic in 83% and tumor EBV+ 94%. Further, 33% deep brain involvement, 10% CSF while none ocular disease. Immunosuppression reduced 93%; additional first-line therapy included high-dose methotrexate (48%),...
Burkitt lymphoma is an aggressive B-cell curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment acutely toxic late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R) may obviate the need for highly in adults lymphoma.We conducted a multicenter risk-adapted study of DA-EPOCH-R untreated adult lymphoma. Low-risk patients received three cycles without CNS prophylaxis,...
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) a rare erythrodermic leukemic CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy often necessary for treatment advanced-stage disease. Systemic options have evolved in recent years approval novel agents such as romidepsin, brentuximab vedotin, mogamulizumab. These...
Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin (cHL) and diffuse large B-cell (DLBCL). However, there remains complexity in establishing diagnosis, delineating prognosis, determining optimum therapy. Sixty-eight cases diagnosed GZL across 15 North American academic centers were evaluated by central pathology review to achieve consensus. Of these, only 26 (38%) confirmed GZL. Morphology was critical consensus diagnosis (eg, tumor cell richness);...
Natural killer (NK)/T-cell lymphomas are a rare and distinct subtype of non-Hodgkin's lymphomas. NK/T-cell predominantly extranodal most these nasal type, often localized to the upper aerodigestive tract. Because (ENKL) malignancies, randomized trials comparing different regimens have not been conducted date standard therapy has yet established for patients. These NCCN Guidelines Insights discuss recommendations diagnosis management patients with ENKL as outlined in T-Cell Lymphomas.
Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of associated with an aggressive clinical course and worse prognosis. HSTCL develops in the setting chronic immune suppression or dysregulation up to 20% cases most often characterized by spleen, liver, bone marrow involvement. Diagnosis management pose significant challenges given rarity disease along absence lymphadenopathy poor outcome conventional chemotherapy regimens. These Guidelines Insights focus on diagnosis treatment as...
Abstract Data addressing prognostication in patients with HIV related Burkitt lymphoma (HIV-BL) currently treated remain scarce. We present an international analysis of 249 (United States: 140; United Kingdom: 109) HIV-BL from 2008 to 2019 aiming identify prognostic factors and outcomes. With a median follow up 4.5 years, the 3-year progression-free survival (PFS) overall (OS) were 61% (95% confidence interval [CI] 55% 67%) 66% (95%CI 59% 71%), respectively, similar results both countries....
The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials patients with peripheral T-cell lymphoma (PTCL), cutaneous (CTCL), or B-cell non-Hodgkin (NHL). objective this research was examine relationship between expression level clinical response BV.We analyzed treated BV monotherapy 5 prospective studies relapsed refractory PTCL, CTCL, NHL. by immunohistochemistry (IHC) using Ber H2 antibody for 275...
Tenalisib, a selective phosphoinositide-3-kinase δ/γ, and salt-inducible-kinase-3 inhibitor has shown efficacy was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest synergistic anti-tumor potential for the combination of tenalisib histone-deacetylase inhibitor, romidepsin. This multicenter, open-label, phase I/II study designed to characterize safety, pharmacokinetics oral twicedaily (BID) intravenous (IV) romidepsin administered on Days 1, 8 15 28-day cycles...
Abstract Introduction Angioimmunoblastic T‐cell lymphoma (AITL) is a rare and aggressive with poor prognosis. AITL associated Epstein–Barr virus (EBV)‐positive B cells in most cases, suggesting possible role for the pathobiology of AITL. Cell lines from patients do not exist models human are needed. We aim to establish such model use it preclinical therapeutic evaluation. Methods Primary lymph node tissue an patient was used tumor cell isolation injection NSG mice. The established...
Summary Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma ( FL ) patients. The safety and efficacy of maintenance MR after BR induction has not been formally compared to observation , resulting in disparate practice patterns. Prospective trials have shown benefit R‐ CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or CVP prednisone), yet recent data from the GALLIUM study comparing outcomes patients treated...
<h2>Abstract</h2> High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is frequently performed in patients with hematologic malignancies. ASCT can result significant nausea, pain, and discomfort. Supportive care has improved, pharmacologic therapies are used, but limitations. Music been demonstrated to improve nausea pain undergoing chemotherapy, little data available regarding the effects of music therapy setting. In a prospective study, lymphoma or multiple...
Central nervous system (CNS) involvement in Burkitt lymphoma (BL) poses a major therapeutic challenge, and the relative ability of contemporary regimens to treat CNS remains uncertain. We described prognostic significance incidence recurrence/progression after immunochemotherapy using real-world clinicopathologic data on adults with BL diagnosed between 2009 2018 across 30 US institutions. examined associations baseline involvement, patient characteristics, complete response (CR) rates,...
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed validated novel index specific for BL to aid risk stratification, interpretation of trials, targeted development treatment approaches.We derived the International Prognostic Index (BL-IPI) from real-world data set adult patients with treated immunochemotherapy in United States between 2009 2018, identifying candidate variables that showed strongest association progression-free...